About US
Contact us
-
Post-Shire buy, Takeda investors want executives to return pay if performance lagsTakeda wrapped up its $60 billion Shire takeoverearly this year with massive support from shareholders, despite previous resistance. But the weight on the deal's mastermind, Takeda CEO Christophe W2019/7/3
-
Novartis struggling to win payer coverage for $2.1M gene therapy Zolgensma: analystsOnly about one-third of the top 30 U.S. insurance companies have made their decisions about how to cover Novartis’ new $2.1 million gene therapy to treat spinal muscular atrophy (SMA), Zolgensma, but2019/7/2
-
Warren blasts Gottlieb's jump to Pfizer, but ex-FDA chief says he's 'proud'Scott Gottlieb and Pfizer surely knew critics would challenge the former FDA commissioner’s decision to join the pharma giant's board—less than three months after his departure from the agency, no le2019/7/2
-
Sanofi, Regeneron's Libtayo hits hot streak with EU green light, NICE backingSanofi and Regeneron’s Libtayo is two for two in the last two days—with European officials, that is. One day after the European Commissionclearedthe PD-1 drug to treat cutaneous squamous cell carcino2019/7/1
-
GSK taps NASCAR favorite to drive awareness of new Nicorette lozengeNASCAR driver Dale Earnhardt Jr. is taking the wheel for GlaxoSmithKline’s new Nicorette innovation—a better-tasting ice mint lozenge. The campaign, “Taste Test Drive,” features Earnhardtdriving and2019/7/1
-
Novartis' Gilenya staves off generic challengers—for now—after federal injunctionNovartis’ multiple sclerosismed Gilenya is facing U.S. generic challengers on all sides to its blockbuster sales,and the company hoped a court order could stave them off. The Swiss drugmaker got what2019/6/28
-
Sanofi and Regeneron's Dupixent scores 3rd FDA approval in sinusitis with nasal polypsSanofi and Regeneron’s Dupixent has been charging ahead since its initial approval in moderate-to-severe atopic dermatitis, later picking up a follow-up nod in moderate-to-severe asthma. Wednesday,2019/6/28
-
Analysts rip into AbbVie, Allergan's $63B deal, citing culture clash, strategy concerns and moreAbbVie made a major splash Tuesdaywith its proposed $63 billionbuyoutof Allergan that’ll create a top-5 pharma giant. But analysts and investors were hardly impressed. One day after the announcemen2019/6/27
-
FDA fast-tracks BI, Lilly's Jardiance in chronic heart failureWhen Boehringer Ingelheim and Eli Lilly’s diabetes med Jardiance first showed CV benefits in trial patients, it changed the game for the SGLT2 inhibitor class. Now, not content to reston its laurels,2019/6/26
-
Novartis manufacturing agreement cited in Syria controversyNovartis has found itself caught up in a controversy about ingredients shipped to Syria that critics say could have been used to make sarin gas. The report from Swiss media focused on German chemical2019/6/26